90 citations
,
August 2006 in “British Journal of Dermatology” This paper describes the PRIDE syndrome associated with epidermal growth factor receptor inhibitors but reports no new clinical results.
3 citations
,
January 2019 in “Indian Journal of Drugs in Dermatology” This study reports two cases of PRIDE complex in nonsmall cell lung cancer patients treated with erlotinib and gefitinib, highlighting cutaneous reactions like papulopustules and paronychia.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” This case report describes a 64-year-old man with advanced colorectal cancer developing cutaneous side effects from panitumumab, highlighting the importance of early diagnosis and treatment to improve quality of life and therapy continuation.
August 2025 in “JEADV Clinical Practice” This case report describes the management of PRIDE complex, a skin and hair condition associated with EGFR inhibitor treatment like cetuximab, emphasizing that it does not require stopping the medication.
This case study documents a 55-year-old male with advanced NSCLC who experienced toe-predominant paronychia and a papulopustular rash following dacomitinib treatment, with the causality tools indicating a "probable" link, yet the therapy continued successfully without dosage alteration.